Results 41 to 50 of about 2,455 (143)

Evaluation of a pantoprazole and 4‐desmethylpantoprazole‐sulfate metabolic ratio as a novel CYP2C19 phenotyping method

British Journal of Clinical Pharmacology, EarlyView.
Aims CYP2C19 is one of the most important pharmacogenes, and its activity is highly variable due to factors such as genetics or drug–drug interactions. Due to the lack of an appropriate endogenous CYP2C19 biomarker, surrogate methods to assess its activity are warranted.
Julian Peter Müller, Vladimir N. Belov, Sabrina Yamoune, Bob Miller, Mohammed Hasoumi, Jolanta Tupiec, Thea Laurentius, L. Cornelius Bollheimer, Julia C. Stingl, Katja S. Just   +9 more
wiley   +1 more source

Clinical relevance of pharmacogenomic information for improving prescribing practices in acutely admitted older medical patients

British Journal of Clinical Pharmacology, EarlyView.
Aims Safe prescribing and effective medication review during acute hospitalization depends on accurate information about liver and kidney function because these organs are responsible for the elimination of most medications. While estimates for kidney function are widely used, comparable markers of hepatic drug‐metabolizing capacity are not routinely ...
Louise Westberg Strejby Christensen, Anne Kirstine Boas, Emilie Clausen, Nicoline Elers Koch, Anne Byriel Walls, Lotte Stig Nørgaard, Michael Asger Andersen, Anissa Aharaz, Rikke Lundsgaard Nielsen, Olivia Bornæs, Juliette Tavenier, Baker Nawfal Jawad, Helle Gybel Juul‐Larsen, Esben Iversen, Ove Andersen, Lona Louring Christrup, Kim Peder Dalhoff, Morten Baltzer Houlind   +17 more
wiley   +1 more source

Cerebrospinal-fluid biomarkers for predicting phenoconversion in patients with isolated rapid-eye movement sleep behavior disorder

, 2023
study objectives patients with isolated rapid-eye-movement sleep behavior disorder (iRBD) have an increased risk of developing neurodegenerative diseases.
Calvello, C, Nuccetelli, M, Maio, S, Sergio Bernardini, Claudio Liguori, Matteo Spanetta, Clementina Lupo, Paolo Eusebi, Fernandes, M, Bernardini, S, Mariana Fernandes, Carmen Calvello, Spanetta, M, Nicola Biagio Mercuri, Eusebi, P, Mercuri, NB, Liguori, C, Silvia Maio, Placidi, F, Claudia De Masi, Izzi, F, De Masi, C, Fabio Placidi, Lupo, C, Marzia Nuccetelli, Francesca Izzi   +25 more
core   +1 more source

Clinical Functional Assignment of TPMT and NUDT15 Alleles by the Clinical Pharmacogenetics Implementation Consortium Pharmacogene Curation Expert Panel

Clinical Pharmacology &Therapeutics, EarlyView.
The Clinical Pharmacogenetics Implementation Consortium (CPIC) TPMT/NUDT15 Pharmacogene Curation Expert Panel (PCEP) conducted a comprehensive review of clinical, laboratory, and computational evidence to determine the clinical function assignments for TPMT and NUDT15 star alleles.
Bailey M. Tibben, Maud Maillard, Victoria M. Pratt, Ann M. Moyer, Debbie M. Figueroa, Michelle Whirl‐Carrillo, Andrea Gaedigk, Gabriele Stocco, Matthias Schwab, Kelly E. Caudle, Jun J. Yang   +10 more
wiley   +1 more source

Pharmacist-Led Medication Evaluation Considering Pharmacogenomics and Drug-Induced Phenoconversion in the Treatment of Multiple Comorbidities: A Case Report

Medicina, 2021
Pharmacogenomic (PGx) information can guide drug and dose selection, optimize therapy outcomes, and/or decrease the risk of adverse drug events (ADEs). This report demonstrates the impact of a pharmacist-led medication evaluation, with PGx assisted by a ...
Nicole Marie Del Toro-Pagán, Adriana Matos, David Thacker, Jacques Turgeon, Nishita Shah Amin, Veronique Michaud   +5 more
doaj   +1 more source

Dispensing of actionable pharmacogenetic drugs among adults receiving cardiovascular disease medications in the Northern Netherlands: A serial cross‐sectional study

Clinical Pharmacology &Therapeutics, EarlyView.
The extent of pharmacogenetic (PGx) drug dispensing among Dutch adults receiving medications for cardiovascular disease (CVD) is unknown. Using the University of Groningen IADB.nl pharmacy database, we performed a serial cross‐sectional study (2019–2023) to estimate the annual prevalence of PGx drug dispensing and annual rates of initiation.
Zhuolin Zhang, Guiling Zhou, Jens H. J. Bos, Eelko Hak, Talitha Feenstra, Frank Klont   +5 more
wiley   +1 more source

Phenoconversion of CYP3A4, CYP2C19 and CYP2D6 in Pediatrics, Adolescents and Young Adults With Lymphoma: Rationale and Design of the PEGASUS Study

Clinical and Translational Science
Phenoconversion is the discrepancy between genotype‐predicted phenotype and clinical phenotype, due to nongenetic factors. In oncology patients, the impact of phenoconversion on drug selection, efficacy, toxicity, and treatment outcomes is unknown.
Rachel Conyers, Tayla Stenta, Andrew A. Somogyi, Carl Kirkpatrick, Andreas Halman, Sophie Wang, Claire Moore, Dhrita Khatri, Elizabeth Williams, Roxanne Dyas, Tim Spelman, David A. Elliott, Amanda Gwee, Marliese Alexander   +13 more
doaj   +1 more source

Tracking Genetic Parkinson's Disease with Molecular Imaging: A Systematic Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is a worldwide, complex neurodegenerative disorder influenced by both genetic and environmental factors. Around 15–20% of PD cases are linked to genetic mutations, providing insights into the disease's pathogenesis.
Chiara Meneghini, Luca Gallo, Arianna Sala, Enza Maria Valente, Micol Avenali, Silvia Paola Caminiti   +5 more
wiley   +1 more source

Precision anesthesia and pharmacogenomics: a scoping review of personalized drug response

Frontiers in Anesthesiology
BackgroundAnesthetic agent selection and dosing have historically relied on empirical models without taking into account inter-individual variability in drug response, leading to adverse drug reactions (ADRs).
Sarina Nikzad, Ofelia Loani Elvir-Lazo, Robert Wong   +2 more
doaj   +1 more source

Melanopsin‐Mediated Post‐Illumination Pupillary Response in Idiopathic Rapid Eye Movement (REM) Sleep Behavior Disorder and Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Aims To conduct a case–control study to investigate melanopsin‐mediated post‐illumination pupillary response (PIPR) in patients with Parkinson's disease (PD), video‐polysomnography‐confirmed isolated/idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD), and age‐matched healthy controls (HC). Methods PIPR was measured at 6 s after
Joey W.Y. Chan, Bei Huang, Siyi Gong, Yuhua Yang, Shi Tang, Steven Wai‐ho Chau, Ngan Yin Chan, Tim Man‐ho Li, Yaping Liu, Anne Y.Y. Chan, Karen K.Y. Ma, Shirley X. Li, Joshua Tsoh, Kelvin K.L. Chong, Kathryn A. Roecklein, Vincent C.T. Mok, Yun Kwok Wing   +16 more
wiley   +1 more source